



易慕峰
IMMUNOFOCO



Vision for Cure of Solid Tumors with Cell Therapies

DRIVING THE NEXT WAVE OF CELL THERAPY INDUSTRY



Apr 2025

IMMUNOFOCO Products Designed to Fulfill the Unmet Medical Needs



Pipeline	Indication	Pre-clinical	IIT	IND	Phase I	Pivotal	Rights	Status
IMC001 EpCAM CAR-T	Solid Tumors	<div></div>					Global	<div></div> <div></div>
IMC002 CLDN18.2 CAR-T	CLDN18.2 positive Advanced Solid Tumors	<div></div>					Global	<div></div> <div></div>
IMC008 SNR Next-Gen CAR-T	Solid Tumors	<div></div>					Global	<div></div> <div></div> <div></div>
IMC003 Peri Cruiser®-T	Solid Tumors	<div></div>					Global	<div></div>
IMC004 T-Booster	Solid Tumors	<div></div>					Global	<div></div>
IMC006 Universal NK cell	Autoimmune diseases	<div></div>					Global	<div></div>
Undisclosed IN VIVO CAR-T	Undisclosed	<div></div>					Global	<div></div>



Clinical stage Orphan drug CAR-T Platforms

IMC001 EpCAM CAR-T

US & CN IND

Preliminary Safety and Efficacy Data Observed in IIT

- **Sep, 2023**
 - ODD been granted by US FDA
- **Feb, 2024**
 - IND approval from both China CDE and US FDA for GI cancers
- **Jan, 2025**
 - IND approval from China CDE for pan-epithelial-derived tumors (TNBC, SCLC, etc.)

- GC patients in IIT study:
 - DCR 90%, ORR 30%
 - ORR 40%, mOS 55wks in RP2D group
- More potential indications such as TNBC, SCLC...



IMC002 CLDN18.2 CAR-T


US/CN IND; Pivotal Phase II Ready in China

Advanced Gastric Cancer +

Pancreatic Cancer

- **Jul, 2022**
 - ODD been granted by US FDA
- **Mar, 2023**
 - IND approval from both China CDE and US FDA
- **Dec, 2024**
 - FTD been granted by US FDA
 - EOP1 meeting request submitted
- VHH binder with high specificity, superior safety profiles in preclinical
- BIC potential with ORR high than 60% and mPFS longer than 6.9 months in end-line GC patients
- Well tolerated safety profiles

Next Generation Platforms to Improve Efficacy/Safety and Accessibility



Clinical stage assets

- Licensing (ex-China) globally or regional
- New-Co (ex-China rights)

Preclinical assets & platforms

- Co-development (preclinical assets)
- Technology licensing (platform)
- Spin-off (assets or platforms)

THANK YOU

Collaboration with
global talents

Curing cancer with
dedication

Courage to
accomplish



www.immunofoco.com
BD@immunofoco.com